S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Canopy Growth (CGC) Stock Forecast, Price & News

-0.35 (-5.96%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
6.38 million shs
Average Volume
5.40 million shs
Market Capitalization
$2.18 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CGC News and Ratings via Email

Sign-up to receive the latest news and ratings for Canopy Growth and its competitors with MarketBeat's FREE daily newsletter.

Canopy Growth logo

About Canopy Growth

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.


See More Headlines

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$414.03 million
Book Value
$6.90 per share


Net Income
$-1.32 billion
Pretax Margin




Free Float
Market Cap
$2.18 billion

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End


Overall MarketRank

1.03 out of 5 stars

Medical Sector

1239th out of 1,416 stocks

Medicinals & Botanicals Industry

17th out of 21 stocks

Analyst Opinion: 2.8Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Canopy Growth (NASDAQ:CGC) Frequently Asked Questions

Is Canopy Growth a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Canopy Growth in the last year. There are currently 6 sell ratings, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Canopy Growth stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CGC, but not buy additional shares or sell existing shares.
View analyst ratings for Canopy Growth
or view top-rated stocks.

When is Canopy Growth's next earnings date?

Canopy Growth is scheduled to release its next quarterly earnings announcement on Friday, May 27th 2022.
View our earnings forecast for Canopy Growth

How can I listen to Canopy Growth's earnings call?

Canopy Growth will be holding an earnings conference call on Friday, May 27th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Canopy Growth's earnings last quarter?

Canopy Growth Co. (NASDAQ:CGC) released its quarterly earnings results on Friday, November, 5th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.14. The firm earned $145.70 million during the quarter, compared to analyst estimates of $145.63 million. Canopy Growth had a negative net margin of 71.43% and a negative trailing twelve-month return on equity of 15.71%. The firm's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 earnings per share.
View Canopy Growth's earnings history

What price target have analysts set for CGC?

12 Wall Street analysts have issued 12 month price targets for Canopy Growth's stock. Their forecasts range from $7.00 to $55.00. On average, they expect Canopy Growth's share price to reach $16.18 in the next twelve months. This suggests a possible upside of 193.1% from the stock's current price.
View analysts' price targets for Canopy Growth
or view top-rated stocks among Wall Street analysts.

Who are Canopy Growth's key executives?
Canopy Growth's management team includes the following people:
  • Mr. David Eric Klein, CEO & Director (Age 58, Pay $2.79M)
  • Mr. Julious C. Grant Jr., Chief Commercial Officer (Age 54, Pay $686.07k)
  • Ms. Judy Eunjoo Hong, VP of Investor Relations & Competitive Intelligence, Chief of Staff to the CEO and CFO (Age 49)
  • Mr. Jonathan Di Tosto, Chief Operations Officer
  • Mr. Thomas Carlton Stewart, VP & Chief Accounting Officer (Age 40)
  • Mr. Thomas Shipley IV, Sr. VP of Quality Assurance & Chief Science Officer (Age 33)
  • Ms. Holly Lukavsky, Chief HR Officer
  • Mr. Timothy Rob Saunders F.C.A., FCPA, Strategic Advisor (Age 61)
  • Jason Green, Head of Agriculture - Hemp Division
  • Dr. Mark A. Ware, Chief Medical Officer
What is Canopy Growth's stock symbol?

Canopy Growth trades on the NASDAQ under the ticker symbol "CGC."

Who are Canopy Growth's major shareholders?

Canopy Growth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.00%), Contrarius Investment Management Ltd (0.53%), Goldman Sachs Group Inc. (0.00%), Swiss National Bank (0.27%), Mirae Asset Global Investments Co. Ltd. (0.22%) and JPMorgan Chase & Co. (0.21%). Company insiders that own Canopy Growth stock include Phillip Stephen Shaer, Rade Nikola Kovacevic and Tomas Iv Shipley.
View institutional ownership trends for Canopy Growth

Which institutional investors are selling Canopy Growth stock?

CGC stock was sold by a variety of institutional investors in the last quarter, including Bank of Nova Scotia, Cibc World Market Inc., Goldman Sachs Group Inc., The Manufacturers Life Insurance Company , Walleye Trading LLC, Ergoteles LLC, SIG North Trading ULC, and Wolverine Asset Management LLC.
View insider buying and selling activity for Canopy Growth
or view top insider-selling stocks.

Which institutional investors are buying Canopy Growth stock?

CGC stock was acquired by a variety of institutional investors in the last quarter, including Contrarius Investment Management Ltd, Prentice Capital Management LP, Bank of Montreal Can, Vanguard Group Inc., Sculptor Capital LP, Sculptor Capital LP, GMT Capital Corp, and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
View insider buying and selling activity for Canopy Growth
or or view top insider-buying stocks.

How do I buy shares of Canopy Growth?

Shares of CGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Canopy Growth's stock price today?

One share of CGC stock can currently be purchased for approximately $5.52.

How much money does Canopy Growth make?

Canopy Growth has a market capitalization of $2.18 billion and generates $414.03 million in revenue each year. The company earns $-1.32 billion in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Canopy Growth have?

Canopy Growth employs 3,259 workers across the globe.

What is Canopy Growth's official website?

The official website for Canopy Growth is www.canopygrowth.com.

How can I contact Canopy Growth?

Canopy Growth's mailing address is 1 HERSHEY DRIVE, SMITH FALLS A6, K7A0A8. The company can be reached via phone at (855) 558-9333 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.